Corona Remedies IPO Review | Strong Financials, 65% PAT Growth | Subscribe For Gains?

Corona Remedies has opened its IPO from 8th to 10th December, with a price band of ₹1008 - ₹1062 per share and a market cap of ₹6,495 crore. The issue size is ₹655 crore, entirely an offer for sale, with anchors already investing ₹194 crore. Employees receive a ₹54 discount per share. The Indian pharma company focuses on women’s healthcare, cardiology, pain management, urology and multispecialty segments, operating with 71 brands. Financials show strong momentum with 18% revenue growth and 65% PAT growth YoY. With stable market share and valuations at 35x P/E, analysts see potential listing gains along with long-term investment attractiveness. Overall expert view: Subscribe for listing and long-term.